Literature DB >> 16611884

The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation.

Shuang Tang1, Mingfang Tao, J Philip McCoy, Zhi-Ming Zheng.   

Abstract

High-risk human papillomaviruses (HPVs) encode two viral oncoproteins, E6 and E7, from a single bicistronic pre-mRNA containing three exons and two introns. Retention of intron 1 in the E6 coding region is essential for production of the full-length E6 oncoprotein. However, splicing of intron 1 is extremely efficient in cervical cancer cells, leading to the production of a spliced transcript, E6*I, of E6. Here, we investigated whether this splicing of intron 1 might benefit E7 production. Using RNA interference as a tool, we targeted the intron 1 region using small interfering RNAs (siRNAs) in HPV-positive cell lines. At an effective low dose, the siRNAs specifically suppressed E6 expression but not E7 expression, as demonstrated by the stabilization of p53. However, at high doses the HPV18 intron 1-specific siRNA substantially and specifically reduced the level of the 18E6*I mRNA lacking the intron region in HeLa cells, implying its nuclear silencing on the pre-mRNA before RNA splicing. Two other siRNAs targeting the exon 2 regions of HPV16 and -18, which encode the E7 oncoprotein, reduced the E6*I mRNAs to a remarkable extent and preferentially suppressed expression of E7, leading to accumulation of hypophosphorylated p105Rb and cell cycle arrest, indicating that the majority of E7 proteins are the translational products of E6*I mRNAs. This was confirmed by transient transfection in 293 cells: E7 could be translated only from the E7 open reading frame (ORF) on E6*I mRNA in a distance-dependent matter of upstream E6*I ORF by translation reinitiation. The data thus provide direct evidence that the E6*I mRNAs of high-risk HPVs are responsible for E7 production.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611884      PMCID: PMC1472016          DOI: 10.1128/JVI.80.9.4249-4263.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA.

Authors:  S N Stacey; D Jordan; A J Williamson; M Brown; J H Coote; J R Arrand
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Control of E2F activity by p21Waf1/Cip1.

Authors:  L Delavaine; N B La Thangue
Journal:  Oncogene       Date:  1999-09-23       Impact factor: 9.867

Review 3.  Papillomaviruses and cancer: from basic studies to clinical application.

Authors:  Harald zur Hausen
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

4.  In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA.

Authors:  Mitsuo Yoshinouchi; Taketo Yamada; Masahiro Kizaki; Jin Fen; Takeyoshi Koseki; Yasuo Ikeda; Tatsuji Nishihara; Kenji Yamato
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.

Authors:  Ming Jiang; Jo Milner
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

7.  Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes.

Authors:  Baojin Fu; Jesse Quintero; Carl C Baker
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

8.  siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells.

Authors:  Karin Butz; Tutik Ristriani; Arnd Hengstermann; Claudia Denk; Martin Scheffner; Felix Hoppe-Seyler
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

9.  Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells.

Authors:  Rosa Anna DeFilippis; Edward C Goodwin; Lingling Wu; Daniel DiMaio
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 10.  Pushing the limits of the scanning mechanism for initiation of translation.

Authors:  Marilyn Kozak
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

View more
  96 in total

1.  Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Authors:  Daniela Ehehalt; Barbara Lener; Haymo Pircher; Kerstin Dreier; Heiko Pfister; Andreas M Kaufmann; Sergio Frangini; Sigrun Ressler; Elisabeth Müller-Holzner; Markus Schmitt; Daniela Höfler; Ursula Rostek; Andreas Kaiser; Andreas Widschwendter; Werner Zwerschke; Pidder Jansen-Dürr
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

Review 2.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

3.  Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.

Authors:  Denise M Schütze; Peter J F Snijders; Leontien Bosch; Duco Kramer; Chris J L M Meijer; Renske D M Steenbergen
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

4.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

5.  HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function.

Authors:  Xuefeng Liu; Jeffrey Roberts; Aleksandra Dakic; Yiyu Zhang; Richard Schlegel
Journal:  Virology       Date:  2008-03-26       Impact factor: 3.616

6.  Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development.

Authors:  Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky
Journal:  J Med Virol       Date:  2009-04       Impact factor: 2.327

7.  Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells.

Authors:  I Martinez; A S Gardiner; K F Board; F A Monzon; R P Edwards; S A Khan
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

8.  The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer.

Authors:  Angela Hong; Xiaoying Zhang; Deanna Jones; Mei Zhang; C Soon Lee; J Guy Lyons; Anne-Sophie Veillard; Barbara Rose
Journal:  Cancer Biol Ther       Date:  2015-11-17       Impact factor: 4.742

Review 10.  Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses.

Authors:  Zhi-Ming Zheng
Journal:  Int J Biol Sci       Date:  2010-12-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.